Quality indicators measuring pharmaceutical care for asthma and chronic obstructive pulmonary disease within primary care: a scoping review

PURPOSE: Despite the growing emphasis on quality improvement, an overview of quality indicators (QIs) measuring pharmaceutical care in asthma and COPD remains limited. Numerous QIs have been developed for general respiratory care, yet often designed for physician-led hospital settings rather than pharmacist-led primary care. This scoping review provides an overview of existing QIs measuring pharmaceutical care for asthma and COPD within primary care, including an evaluation of their clinimetric properties. METHODS: A systematic literature search was conducted across five electronic databases. The population included adult asthma and/or COPD patients; concept aimed at QIs measuring structures, processes, and outcomes; in the context of pharmaceutical care provided by pharmacists in primary care. Selected articles were categorized using a two-stage approach; a study-level classification followed by an indicator-level classification of identified QIs. RESULTS: Of the 46 articles identified 23 articles (47.9%) focused on development, 16 articles (33.3%) on validation, and 9 articles on feasibility (18.8%). Overall, 188 QIs measuring pharmaceutical care for asthma and/or COPD were identified, categorized into five healthcare domains; 1) screening and diagnosis (10.6%), 2) guideline-based pharmacological treatment (21.8%), 3) self-management support (25.0%), 4) referral for expert advice (7.4%) and 5) disease control assessment (35.1%). Identified QIs included structure (1.6%), process (81.9%) and outcome (16.5%). 155 QIs (82.4%) were evaluated on development-related metrics, 46 QIs (24.5%) on validation and 42 QIs (22.3%) on feasibility. CONCLUSION: A vast overview of QIs have been identified for pharmaceutical care in asthma and COPD, noting their practical utility and validation depends on their applicability for internal clinical improvement or external 'pay-for-performance' schemes.

Authors

Institutions

Publication Details

Journal
American Journal of Health-System Pharmacy
Published
2026-09-11
DOI
https://doi.org/10.1093/ajhp/zxag277
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Quality indicators measuring pharmaceutical care for asthma and chronic obstructive pulmonary disease within primary care: a scoping review

Claire D. Visser, Martina Teichert, Henk-Jan Guchelaar
American Journal of Health-System Pharmacy
Pharmaceutical Practices and Patient Outcomes
article

Quality indicators measuring pharmaceutical care for asthma and chronic obstructive pulmonary disease within primary care: a scoping review

Claire D. Visser, Martina Teichert, Henk-Jan Guchelaar
article en

Abstract

PURPOSE: Despite the growing emphasis on quality improvement, an overview of quality indicators (QIs) measuring pharmaceutical care in asthma and COPD remains limited. Numerous QIs have been developed for general respiratory care, yet often designed for physician-led hospital settings rather than pharmacist-led primary care. This scoping review provides an overview of existing QIs measuring pharmaceutical care for asthma and COPD within primary care, including an evaluation of their clinimetric properties. METHODS: A systematic literature search was conducted across five electronic databases. The population included adult asthma and/or COPD patients; concept aimed at QIs measuring structures, processes, and outcomes; in the context of pharmaceutical care provided by pharmacists in primary care. Selected articles were categorized using a two-stage approach; a study-level classification followed by an indicator-level classification of identified QIs. RESULTS: Of the 46 articles identified 23 articles (47.9%) focused on development, 16 articles (33.3%) on validation, and 9 articles on feasibility (18.8%). Overall, 188 QIs measuring pharmaceutical care for asthma and/or COPD were identified, categorized into five healthcare domains; 1) screening and diagnosis (10.6%), 2) guideline-based pharmacological treatment (21.8%), 3) self-management support (25.0%), 4) referral for expert advice (7.4%) and 5) disease control assessment (35.1%). Identified QIs included structure (1.6%), process (81.9%) and outcome (16.5%). 155 QIs (82.4%) were evaluated on development-related metrics, 46 QIs (24.5%) on validation and 42 QIs (22.3%) on feasibility. CONCLUSION: A vast overview of QIs have been identified for pharmaceutical care in asthma and COPD, noting their practical utility and validation depends on their applicability for internal clinical improvement or external 'pay-for-performance' schemes.

American Journal of Health-System Pharmacy
Leiden University Medical Center (NL), Royal Dutch Pharmacists Association (NL)
Openalex Percentile: Top 14%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.